{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:19:15Z","timestamp":1791263955174,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2009,9,1]],"date-time":"2009-09-01T00:00:00Z","timestamp":1251763200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Lymphoma and Myeloma"],"published-print":{"date-parts":[[2009,9]]},"DOI":"10.3816\/clm.2009.s.009","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T10:04:58Z","timestamp":1254218698000},"page":"S179-S185","source":"Crossref","is-referenced-by-count":36,"special_numbering":"S3","title":["Flavopiridol in Chronic Lymphocytic Leukemia: A Concise Review"],"prefix":"10.3816","volume":"9","author":[{"given":"Beth A.","family":"Christian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Grever","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John C.","family":"Byrd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.3816\/CLM.2009.s.009_bib1","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.009_bib2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/blood.V85.2.307.307","article-title":"Advances in the biology and treatment of B-cell chronic lymphocytic leukemia","volume":"85","author":"O'Brien","year":"1995","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib3","first-page":"457","article-title":"Fludarabine monophosphate: a potentially useful agent in chronic lymphocytic leukemia","volume":"30","author":"Grever","year":"1988","journal-title":"Nouv Rev Fr Hematol"},{"key":"10.3816\/CLM.2009.s.009_bib4","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1016\/S0140-6736(96)91681-5","article-title":"Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL","volume":"347","author":"Johnson","year":"1996","journal-title":"Lancet"},{"key":"10.3816\/CLM.2009.s.009_bib5","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2005-06-2395","article-title":"Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia","volume":"107","author":"Eichhorst","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib6","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.009_bib7","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib8","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2004-03-0796","article-title":"Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011","volume":"105","author":"Byrd","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib9","doi-asserted-by":"crossref","first-page":"4070","DOI":"10.1200\/JCO.2005.12.516","article-title":"Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia","volume":"23","author":"Wierda","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.009_bib10","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1182\/blood-2003-10-3729","article-title":"Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions","volume":"103","author":"Lozanski","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib11","first-page":"771a","article-title":"Campath-1H in refractory CLL: complete remission despite p53 gene mutation","volume":"98","author":"Stilgenbauer","year":"2001","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib12","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1056\/NEJM200208083470619","article-title":"Campath-1H-induced complete remission of chronic lymphocytic leukemia despite p53 gene mutation and resistance to chemotherapy","volume":"347","author":"Stilgenbauer","year":"2002","journal-title":"N Engl J Med"},{"key":"10.3816\/CLM.2009.s.009_bib13","doi-asserted-by":"crossref","first-page":"478a","DOI":"10.1182\/blood.V104.11.478.478","article-title":"Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL: Interim analysis of the CLL2H study of the German CLL Study Group (GCLLSG)","volume":"104","author":"Stilgenbauer","year":"2004","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib14","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1007\/s00277-003-0710-5","article-title":"High dose methylprednisolone can induce remissions in CLL patients with p53 abnormalities","volume":"82","author":"Thornton","year":"2003","journal-title":"Ann Hematol"},{"issue":"suppl 1","key":"10.3816\/CLM.2009.s.009_bib15","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1007\/s00280-003-0624-x","article-title":"Novel direct and indirect cyclin-dependent kinase modulators for the prevention and treatment of human neoplasms","volume":"52","author":"Senderowicz","year":"2003","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.3816\/CLM.2009.s.009_bib16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1111\/j.1749-6632.2000.tb06710.x","article-title":"Inhibition of CDKs as a therapeutic modality","volume":"910","author":"Sausville","year":"2000","journal-title":"Ann N Y Acad Sci"},{"key":"10.3816\/CLM.2009.s.009_bib17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jnci\/92.5.376","article-title":"Preclinical and clinical development of cyclindependent kinase modulators","volume":"92","author":"Senderowicz","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2009.s.009_bib18","first-page":"2973","article-title":"Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells","volume":"56","author":"Carlson","year":"1996","journal-title":"Cancer Res"},{"key":"10.3816\/CLM.2009.s.009_bib19","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/jnci\/84.22.1736","article-title":"Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275","volume":"84","author":"Kaur","year":"1992","journal-title":"J Natl Cancer Inst"},{"key":"10.3816\/CLM.2009.s.009_bib20","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1016\/0006-2952(93)90590-S","article-title":"Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells: correlation with decreased H1 kinase activity","volume":"46","author":"Worland","year":"1993","journal-title":"Biochem Pharmacol"},{"key":"10.3816\/CLM.2009.s.009_bib21","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1097-2765(03)00526-4","article-title":"Coordination of transcription, RNA processing, and surveillance by TEFb kinase on heat shcok genes","volume":"13","author":"Ni","year":"2004","journal-title":"Mol Cell"},{"key":"10.3816\/CLM.2009.s.009_bib22","doi-asserted-by":"crossref","first-page":"31793","DOI":"10.1074\/jbc.M102306200","article-title":"Flavopiridol inactivates P-TEFb and blocks most RNA polymerase II transcription in vivo","volume":"276","author":"Chao","year":"2001","journal-title":"J Biol Chem"},{"key":"10.3816\/CLM.2009.s.009_bib23","article-title":"Genomic-scale measurement of mRNA turnover and the mechanisms of action of the anti-cancer drug flavopiridol. Genome Biol 2001; 2:RESEARCH0041","author":"Lam","year":"2001","journal-title":"Epub"},{"key":"10.3816\/CLM.2009.s.009_bib24","doi-asserted-by":"crossref","first-page":"3190","DOI":"10.1182\/blood-2007-10-115733","article-title":"Flavopiridol causes early mitochondrial damage in chronic lymphocytic leukemia cells with impaired oxygen consumption and mobilization of intracellular calcium","volume":"111","author":"Hussain","year":"2008","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib25","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1182\/blood.V91.9.3379","article-title":"Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses","volume":"91","author":"Kitada","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood.V96.2.393","article-title":"Protein kinase inhibitors flavopiridol and 7-hydroxy-staurosporine down-regulate antiapoptosis proteins in B-cell chronic lymphocytic leukemia","volume":"96","author":"Kitada","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib27","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1182\/blood.V92.10.3804","article-title":"Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53","volume":"92","author":"Byrd","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1182\/blood.V91.2.458","article-title":"Early induction of apoptosis in hematopoietic cell lines after exposure to flavopiridol","volume":"91","author":"Parker","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib29","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1200\/JCO.1998.16.9.2986","article-title":"Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms","volume":"16","author":"Senderowicz","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.009_bib30","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1200\/JCO.2001.19.7.1985","article-title":"Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma","volume":"19","author":"Schwartz","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.009_bib31","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1200\/JCO.2002.08.080","article-title":"Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors","volume":"20","author":"Schwartz","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.009_bib32","first-page":"1590","article-title":"A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV nonsmall cell lung cancer","volume":"7","author":"Shapiro","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.009_bib33","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.2000.18.2.371","article-title":"Flavopiridol, a novel cyclin-dependent kinase inhibitor, in metastatic renal cancer: a University of Chicago phase II consortium study","volume":"18","author":"Stadler","year":"2000","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.009_bib34","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1080\/10428190290016908","article-title":"Seventy-two hour continuous infusion flavopiridol in relapsed and refractory mantle cell lymphoma","volume":"43","author":"Lin","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.3816\/CLM.2009.s.009_bib35","first-page":"562","article-title":"Flavopiridol-related proinflammatory syndrome is associated with induction of interleukin-6","volume":"9","author":"Messmann","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.009_bib36","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/j.leukres.2005.03.010","article-title":"Flavopiridol administered as a 24-hour continuous infusion in chronic lymphocytic leukemia lacks clinical activity","volume":"29","author":"Flinn","year":"2005","journal-title":"Leuk Res"},{"key":"10.3816\/CLM.2009.s.009_bib37","doi-asserted-by":"crossref","first-page":"4176","DOI":"10.1158\/1078-0432.CCR-04-2276","article-title":"Treatment of relapsed chronic lymphocytic leukemia by 72-hour continuous infusion or 1-hour bolus infusion of flavopiridol: results from Cancer and Leukemia Group B study 19805","volume":"11","author":"Byrd","year":"2005","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.009_bib38","first-page":"2482","article-title":"Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression, and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts","volume":"91","author":"Arguello","year":"1998","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib39","first-page":"3400","article-title":"Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea","volume":"6","author":"Innocenti","year":"2000","journal-title":"Clin Cancer Res"},{"key":"10.3816\/CLM.2009.s.009_bib40","first-page":"294b","article-title":"Flavopiridol sensitivity of chronic lymphocytic leukemia (CLL) cells in vitro varies based upon species specific drug protein binding","volume":"96","author":"Shinn","year":"2000","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib41","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2006-05-020735","article-title":"Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia","volume":"109","author":"Byrd","year":"2007","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib42","doi-asserted-by":"crossref","first-page":"93a","DOI":"10.1182\/blood.V108.11.302.302","article-title":"Flavopiridol is active in genetically highrisk, relapsed chronic lymphocytic leukemia (CLL): analysis of 56 patients by cytogenetic abnormality","volume":"108","author":"Lin","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib43","doi-asserted-by":"crossref","first-page":"805a","DOI":"10.1182\/blood.V108.11.2845.2845","article-title":"Flavopiridol can be safely dose escalated in relapsed CLL patients: Achievement of target Cmax results in improved clinical activity","volume":"108","author":"Lin","year":"2006","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib44","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1182\/blood-2008-07-168583","article-title":"Clinical response and pharmacokinetics from a phase I study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia","volume":"113","author":"Phelps","year":"2009","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib45","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2009.22.6944","article-title":"A phase II study of flavopiridol (Alvocidib) in relapsed chronic lymphocytic leukemia (CLL): high response rates in genetically high-risk disease","author":"Lin","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.3816\/CLM.2009.s.009_bib46","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.ijpharm.2008.08.008","article-title":"A novel liposomal formulation of flavopiridol","volume":"365","author":"Yang","year":"2009","journal-title":"Int J Pharm"},{"key":"10.3816\/CLM.2009.s.009_bib47","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1038\/sj.leu.2403295","article-title":"Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells","volume":"18","author":"Hahntow","year":"2004","journal-title":"Leukemia"},{"key":"10.3816\/CLM.2009.s.009_bib48","doi-asserted-by":"crossref","first-page":"4484","DOI":"10.1182\/blood-2004-07-2713","article-title":"A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival","volume":"105","author":"Alvi","year":"2005","journal-title":"Blood"},{"key":"10.3816\/CLM.2009.s.009_bib49","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/sj.bjc.6603509","article-title":"A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days","volume":"96","author":"Benson","year":"2007","journal-title":"Br J Cancer"},{"key":"10.3816\/CLM.2009.s.009_bib50","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1021\/jm0305568","article-title":"N-(cycloalkylamino)acyl-2-aminothiazole inhibitors of cyclin-dependent kinase 2. N-[5-[[[5-(1,1-dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a highly efficacious and selective antitumor agent","volume":"47","author":"Misra","year":"2004","journal-title":"J Med Chem"},{"key":"10.3816\/CLM.2009.s.009_bib51","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1593\/neo.07136","article-title":"SNS-032 prevents tumor cell-induced angiogenesis by inhibiting vascular endothelial growth factor","volume":"9","author":"Ali","year":"2007","journal-title":"Neoplasia"},{"key":"10.3816\/CLM.2009.s.009_bib52","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10637-007-9090-3","article-title":"A phase 1 study of SNS-032 (formerly BMS-387032), a potent inhibitor of cyclin-dependent kinases 2, 7 and 9 administered as a single oral dose and weekly infusion in patients with metastatic refractory solid tumors","volume":"26","author":"Heath","year":"2008","journal-title":"Invest New Drugs"}],"container-title":["Clinical Lymphoma and Myeloma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1557919011703377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,22]],"date-time":"2020-05-22T15:47:04Z","timestamp":1590162424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1557919011703377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,9]]},"references-count":52,"alternative-id":["S1557919011703377"],"URL":"https:\/\/doi.org\/10.3816\/clm.2009.s.009","relation":{},"ISSN":["1557-9190"],"issn-type":[{"value":"1557-9190","type":"print"}],"subject":[],"published":{"date-parts":[[2009,9]]}}}